Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine combined with pomalidomide and dexamethasone for first relapsed multiple myeloma with extramedullary lesions
ChiCTR2100048829Phase 4Recruiting
- Sponsor
- Qingdao Municipal Hospital
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bendamustine, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Qingdao Municipal Hospital. Primary endpoint: objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
bendamustinepomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100048829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048829.